The Role of CA-125 in the Management of Ovarian Cancer: A Systematic Review

Overview

Journal Cancer Rep (Hoboken)

Specialty Oncology

Date 2025 Mar 11

PMID 40067023

Authors

Zohre Momenimovahed

Afrooz Mazidimoradi

Leila Allahqoli

Hamid Salehiniya

Affiliations

Soon will be listed here.

Abstract

Background: Ovarian cancer is frequently occurring and fatal for women. CA-125 is important in the screening, diagnosis, and treatment of ovarian cancer. This review study was conducted to explore the influence of CA-125 in addressing ovarian cancer.

Methods: To investigate the role of CA-125 in ovarian cancer, we conducted a comprehensive search for high-quality articles in the Medline, Web of Science Core Collection and Scopus databases using the keywords "ovarian cancer," "ovarian carcinoma," "ovarian neoplasms," and "CA-125" from the 2000 to 2024. We included full-text, peer-reviewed articles in English with relevant keywords published since 2000. We excluded case reports, commentaries, letters to the editor, books, case series, systematic reviews, animal studies, and articles that were not accessible in full text.

Results: After screening the 7947 records, 88 studies were included in this review. In the literature review, it was found that researchers utilized CA-125 for diagnosing ovarian cancer, its predicting, evaluating treatment response, assessing ovarian cancer survival, and early detection of recurrence. In some cases, researchers employed additional tumor markers alongside CA-125 to enhance the test's sensitivity.

Conclusion: CA-125 has become a pivotal marker for ovarian cancer. Its role in the diagnosis, treatment, and ongoing assessment of ovarian cancer cannot be overstated. Continuous monitoring of CA-125 levels can provide comprehensive insights, and categorizing patients as low-risk or high-risk based on CA-125 levels could lead to better outcomes. Integrating CA-125 with other biomarkers may enhance the accuracy of the test and elevate its relevance in patient care.

References

Xu X, Wang Y, Wang F, Jia L, Zhou Y, Deng F . Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer. J Ovarian Res. 2013; 6:31. PMC: 3644248. DOI: 10.1186/1757-2215-6-31. View

van Dalen A, Favier J, Burges A, Hasholzner U, de Bruijn H, Dobler-Girdziunaite D . Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. Gynecol Oncol. 2000; 79(3):444-50. DOI: 10.1006/gyno.2000.5982. View

Parashkevova A, Sehouli J, Richter R, Dimitrova D, Braicu E, Muallem M . Preoperative CA-125 Value as a Predictive Factor for Postoperative Outcome in First Relapse of Platinum-sensitive Serous Ovarian Cancer. Anticancer Res. 2018; 38(8):4865-4870. DOI: 10.21873/anticanres.12799. View

Gupta M, Patel S, Arora R, Tiwari R, Dave P, Desai A . Does preoperative CA-125 cutoff value and percent reduction in CA-125 levels correlate with surgical and survival outcome after neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer? - Our experience from a tertiary cancer institute. South Asian J Cancer. 2020; 9(1):30-33. PMC: 6956573. DOI: 10.4103/sajc.sajc_53_17. View

Lee J, Kim J, Lee Y, Chong G, Hong D . Correlation Between Clinical Outcomes and Serum CA-125 Levels After Standard Treatment for Epithelial Ovarian Cancer. Anticancer Res. 2021; 42(1):349-353. DOI: 10.21873/anticanres.15492. View

Kim B, Park Y, Kim B, Ahn H, Lee K, Chung J . Diagnostic performance of CA 125, HE4, and risk of Ovarian Malignancy Algorithm for ovarian cancer. J Clin Lab Anal. 2018; 33(1):e22624. PMC: 6430343. DOI: 10.1002/jcla.22624. View

Tuxen M, Soletormos G, Dombernowsky P . Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy. Br J Cancer. 2001; 84(10):1301-7. PMC: 2363637. DOI: 10.1054/bjoc.2001.1787. View

Steffensen K, Waldstrom M, Brandslund I, Petzold M, Jakobsen A . The prognostic and predictive value of combined HE4 and CA-125 in ovarian cancer patients. Int J Gynecol Cancer. 2012; 22(9):1474-82. DOI: 10.1097/IGC.0b013e3182681cfd. View

Markman M, Liu P, Rothenberg M, Monk B, Brady M, Alberts D . Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. J Clin Oncol. 2006; 24(9):1454-8. DOI: 10.1200/JCO.2005.04.7373. View

10.

Cao Y, Jiang Y, Lin X, Liu J, Lu T, Cheng W . Dynamic Prediction of Outcome for Patients With Ovarian Cancer: Application of a Joint Model for Longitudinal Cancer Antigen 125 Values. Int J Gynecol Cancer. 2017; 28(1):85-91. DOI: 10.1097/IGC.0000000000001134. View

11.

Rustin G, Marples M, Nelstrop A, Mahmoudi M, Meyer T . Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol. 2001; 19(20):4054-7. DOI: 10.1200/JCO.2001.19.20.4054. View

12.

Karamouza E, Glasspool R, Kelly C, Lewsley L, Carty K, Kristensen G . CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data. Cancers (Basel). 2023; 15(6). PMC: 10047009. DOI: 10.3390/cancers15061823. View

13.

Aliyuda F, Moschetta M, Ghose A, Rallis K, Sheriff M, Sanchez E . Advances in Ovarian Cancer Treatment Beyond PARP Inhibitors. Curr Cancer Drug Targets. 2023; 23(6):433-446. DOI: 10.2174/1568009623666230209121732. View

14.

Andersen M, Goff B, Lowe K, Scholler N, Bergan L, Dresher C . Combining a symptoms index with CA 125 to improve detection of ovarian cancer. Cancer. 2008; 113(3):484-9. PMC: 2734274. DOI: 10.1002/cncr.23577. View

15.

Pavlidis N, Rassy E, Vermorken J, Assi T, Kattan J, Boussios S . The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry. Cancer Epidemiol. 2021; 75:102045. DOI: 10.1016/j.canep.2021.102045. View

16.

Maryam N, Ahmed S, Alam R, Hanif M, Saleem M, Gul R . Role of serum VEGF-A biomarker for early diagnosis of ovarian cancer instead of CA-125. J Pak Med Assoc. 2021; 71(9):2192-2197. DOI: 10.47391/JPMA.05-688. View

17.

Dondi F, Albano D, Bertagna F, Giubbini R . [18F]FDG PET/CT and CA-125 in the evaluation of ovarian cancer relapse or persistence: is there any correlation?. Nucl Med Rev Cent East Eur. 2022; 25(2):78-84. DOI: 10.5603/NMR.a2022.0018. View

18.

Lin Y, Wu C, Fu H, Chen Y, Chen Y, Ou Y . Prognostic significance of elevated pretreatment serum levels of CEA and CA-125 in epithelial ovarian cancer. Cancer Biomark. 2020; 28(3):285-292. DOI: 10.3233/CBM-201455. View

19.

Santillan A, Garg R, Zahurak M, Gardner G, Giuntoli 2nd R, Armstrong D . Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol. 2005; 23(36):9338-43. DOI: 10.1200/JCO.2005.02.2582. View

20.

El-Sherif A, El-Sherif S, Taylor A, Ayakannu T . Ovarian Cancer: Lifestyle, Diet and Nutrition. Nutr Cancer. 2020; 73(7):1092-1107. DOI: 10.1080/01635581.2020.1792948. View